Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Filings indexed 1,264 across all filing types
Latest filing 2019-01-07 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
第三届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 11th meeting of the 3rd Board of Directors of a company. It includes details about the appointment of a general manager, nomination of a new director, amendments to the company bylaws, and the decision to convene an extraordinary shareholders meeting. The document references voting results and independent directors' opinions but does not contain financial data or detailed management discussion. It is clearly a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short and it is not a full report or financial statement, so it is not an Annual Report or Interim Report. Therefore, the classification is MANG with high confidence.
2019-01-07 Chinese
关于修改公司章程的公告
Governance Information Classification · 95% confidence The document is an announcement regarding amendments to the company's articles of association (公司章程). It details specific changes to the company's bylaws, including provisions about share repurchases and board powers. The document states that the amendments will be submitted to the shareholders' meeting for approval. There is no financial data, no report attached, and the document is relatively short (3,716 characters). It is not a full report like an Annual Report or Interim Report, nor is it a certification or voting result announcement. The content focuses on governance rules and changes to the company's internal regulations, which fits the category of Governance Information (CGR).
2019-01-07 Chinese
独立董事关于公司董事长、总经理辞职事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding the resignation of the company's chairman and general manager. It discusses governance matters related to board and management changes, including compliance with regulatory guidelines and the impact on the company's operations. There is no financial data, no mention of financial results, no report publication, or voting results. The content clearly relates to management changes and board composition. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused on management changes, supporting this classification with high confidence.
2019-01-01 Chinese
关于董事长、总经理辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of the company's chairman and general manager, including details about the resignation date, reasons, and interim management arrangements. It does not contain financial data, audit information, or regulatory filings beyond the management change. The content focuses on board and senior management changes, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report or presentation but a formal announcement of management changes.
2019-01-01 Chinese
关于公司主品“护肝片”增加适应症取得临床批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a clinical trial for an existing product's new indication. It includes details about the drug, regulatory approval from the National Medical Products Administration (国家药品监督管理局), and a risk warning to investors. The document is short (1180 characters) and does not contain financial statements or detailed financial analysis. It is an announcement of a regulatory approval event related to the company's product, not a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2018-11-15 Chinese
关于公司实际控制人部分股份解除质押公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company disclosing the release of pledged shares by its actual controller, including detailed data on the number of shares released from pledge, dates, and percentages. It does not contain financial statements, audit information, or management discussion. It is a regulatory announcement about share pledge status changes, which fits the category of Regulatory Filings (RNS) as it does not fit other more specific categories like Share Issue/Capital Change or Director's Dealing. The document length is short and it is an announcement rather than a full report.
2018-11-08 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.